The Worldwide Neurology Patient Monitoring Industry is Expected to Reach $7.4 Billion by 2030
January 26, 2022 07:43 ET
|
Research and Markets
Dublin, Jan. 26, 2022 (GLOBE NEWSWIRE) -- The "Neurology Patient Monitoring Market Size, Share & Trends Analysis Report by Application (Trauma, CSF Management, Migraine, Stroke, Hydrocephalus,...
Early Evaluation of Transcarotid Artery Revascularization (TCAR) Versus Carotid Endarterectomy (CEA) Cost-Effectiveness
December 27, 2021 08:15 ET
|
Society for Vascular Surgery
Rosemont, Ill., Dec. 27, 2021 (GLOBE NEWSWIRE) -- A cost-effectiveness model based on peer-reviewed sources suggests that although five-year costs for transcarotid artery revascularization (TCAR)...
Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2
December 08, 2021 07:04 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical...
Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study
November 19, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study
October 13, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
NovaSignal Secures $37 Million in Series C1
September 28, 2021 09:07 ET
|
NovaSignal Corporation
LOS ANGELES, Sept. 28, 2021 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in the assessment and management of brain health, announced today it has closed...
PathMaker Neurosystems Announces Completion of Pivotal European Clinical Trial Evaluating MyoRegulator® for the Non-Invasive Treatment of Post-Stroke Spasticity
September 27, 2021 05:00 ET
|
PathMaker Neurosystems Inc.
BOSTON and PARIS, Sept. 27, 2021 (GLOBE NEWSWIRE) -- PathMaker Neurosystems Inc., (“PathMaker”), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the...
Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference
September 09, 2021 11:46 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients
September 08, 2021 06:00 ET
|
GNT Pharma Co., Ltd
PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomyFirst multi-target neuroprotectant for the intervention of ischemic brain injurySafety and efficacy verified in two...
Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose
September 07, 2021 07:30 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...